The VMS land grab
Big supplement M&A dominated the headlines. Procter & Gamble kicked things off in August with its $3.8bn purchase of Thorne from L Catterton, seeing off reported interest from Unilever. The purchase signalled that mainstream consumer goods players now see clinically validated, practitioner-trusted VMS brands as a genuine growth category rather than a side bet.
Days later, Japan's Kirin Holdings agreed to a $1.36bn deal for Jamieson Wellness, folding the Canadian heritage brand into a health science portfolio that already includes Blackmores and FANCL.
Then came the flip side of the same coin: the middle of the VMS market is being sorted into "premium and clinical" versus "scale and distribution," with each camp buying differently. For example, Nestlé's $1bn sale of seven VMS brands (including Nature's Bounty, Nuun and Osteo Bi-Flex) to private equity firm Yellow Wood Partners is a case in point. Rather than a retreat from wellness, this was a sharpening of focus: Nestlé opted to keep Solgar and Pure Encapsulations, its premium, science-led names, and offload its mainstream mass-market business to an owner built for that model. Bain Capital's earlier move on Vitabiotics also fitted the same pattern.
Beverages go functional
Nestlé also announced a $5.6bn joint venture with Platinum Equity, spinning off more than 30 water and premium beverage brands — including S.Pellegrino and Perrier — into a new standalone business: Peranel. It's not a nutraceutical deal in the traditional sense, but it confirms that hydration and functional beverages are being treated as a distinct growth platform, with its own R&D team and acquisition mandate.
Expect Peranel to be an active buyer in functional hydration during the next 12-18 months.
Ingredients consolidate around the GLP-1 effect
The ingredients side of the business saw the most consequential deal of the summer: Ingredion's £2.7bn acquisition of Tate & Lyle created a combined $9.9bn ingredient solutions group built around fibre, protein and sugar-reduction. This is squarely aimed at formulators adapting products for GLP-1 users who are eating less but demanding more nutritional density per serving. 
IFF's continued portfolio overhaul ran in parallel, with its Food Ingredients division sold to CVC Capital Partners for $4.3bn and a separate portfolio of speciality natural ingredients businesses picked up by Spain's SuanNutra, which is betting on "visible health" (branded, clinically supported actives) as its growth engine.
MANE's acquisition of citrus specialist Cvista, meanwhile, shows the same consolidation logic playing out at a smaller scale: buying deep trace-compound expertise rather than simply bulk capacity.
Quality infrastructure and emerging markets
There were also two slightly quieter deals, although they matter more than their size suggests. Mérieux NutriSciences' acquisition of testing, inspection and certification firm Certified Group created a combined network of more than 140 labs, underlining how regulatory and quality assurance infrastructure is itself becoming M&A territory as supplement and food safety scrutiny intensifies.
In India, Sun Pharma's acquisition of Innovcare Lifesciences shows pharma majors building nutraceutical and FMCG-style distribution capability to capture demand in a fast-growing, price-sensitive wellness market. This is a trend that’s likely to accelerate as GLP-1 uptake grows in Asian markets too.
What these deals mean for nutra companies
Three things stand out for brands and suppliers watching from the sidelines. First, scientific substantiation is now a genuine pricing lever; nearly every large-cap buyer this summer cited clinical credibility as the rationale.
Second, GLP-1 is no longer just a formulation trend; it's actively steering acquisition strategies in ingredients from fibre and protein to sugar reduction. Third, testing and compliance capacity is consolidating just as fast as brands are, meaning that smaller players may find fewer, larger testing, inspection and certification (TIC) partners to work with going forward.
For a market this fragmented, that combination of forces — premiumisation, GLP-1 reformulation and infrastructure consolidation — is likely to keep dealmakers busy well beyond the summer.
